LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Search

Thermo Fisher Scientific Inc

Cerrado

SectorSanidad

473.92 -3.04

Resumen

Variación precio

24h

Actual

Mínimo

470.84

Máximo

480.22

Métricas clave

By Trading Economics

Ingresos

349M

2B

Ventas

1.1B

12B

P/B

Media del Sector

26.952

57.05

Rentabilidad por dividendo

0.36

Margen de beneficios

16.128

Empleados

125,000

EBITDA

377M

3.2B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+37.33% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.36%

2.52%

Próximas Ganancias

22 abr 2026

Fecha Próximo Dividendo

15 abr 2026

Próxima Fecha de Ex Dividendo

12 jun 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-58B

178B

Apertura anterior

476.96

Cierre anterior

473.92

Noticias sobre sentimiento de mercado

By Acuity

21%

79%

59 / 349 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Thermo Fisher Scientific Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 ene 2026, 11:34 UTC

Ganancias

Thermo Fisher 4Q Profit Rises as Biopharma Spending Rebounds

29 oct 2025, 10:51 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 billion

23 oct 2025, 20:49 UTC

Ganancias

Correction to Thermo Fisher Article on Oct. 22

22 oct 2025, 10:28 UTC

Ganancias

Thermo Fisher 3Q Revenue Rises, Boosted by Life Sciences Business

24 mar 2026, 12:04 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher Completes Acquisition of Clario Holdings for $8.875 Billion >TMO

24 mar 2026, 12:00 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher Scientific Completes Acquisition Of Clario Holdings, Inc. >TMO

29 ene 2026, 11:01 UTC

Ganancias

Thermo Fisher 4Q Organic Revenue Rose 3% >TMO

29 ene 2026, 11:00 UTC

Ganancias

Thermo Fisher: Entering 2026 From Position of Strength >TMO

29 ene 2026, 11:00 UTC

Ganancias

Thermo Fisher 4Q Net $1.96B >TMO

29 ene 2026, 11:00 UTC

Ganancias

Thermo Fisher 4Q Rev $12.22B >TMO

29 ene 2026, 11:00 UTC

Ganancias

Thermo Fisher 4Q EPS $5.21 >TMO

29 ene 2026, 11:00 UTC

Ganancias

Thermo Fisher 4Q Adj EPS $6.57 >TMO

29 oct 2025, 10:06 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher: Clario Provides Endpoint Data Solutions for Clinical Trials >TMO

29 oct 2025, 10:05 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher: Claro Deal Includes Potential Additional Earnout, Other Payments >TMO

29 oct 2025, 10:05 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher to Buy Clario From Group Led by Astorg and Nordic Cap, Novo Holding, Cinven >TMO

29 oct 2025, 10:04 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher Scientific to Pay $8.875 Billion at Closing for Clario Holdings >TMO

29 oct 2025, 10:00 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher Scientific to Acquire Clario Holdings >TMO

22 oct 2025, 10:01 UTC

Ganancias

Thermo Fisher 3Q Organic Revenue Rose 3% >TMO

22 oct 2025, 10:00 UTC

Ganancias

Thermo Fisher: In Great Position to Deliver on 2025 Objectives >TMO

22 oct 2025, 10:00 UTC

Ganancias

Thermo Fisher 3Q Adj EPS $5.79 >TMO

22 oct 2025, 10:00 UTC

Ganancias

Thermo Fisher 3Q Rev $11.12B >TMO

22 oct 2025, 10:00 UTC

Ganancias

Thermo Fisher 3Q Net $1.62B >TMO

22 oct 2025, 10:00 UTC

Ganancias

Thermo Fisher 3Q EPS $4.27 >TMO

2 sept 2025, 12:15 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher Scientific Completes Acquisition Of Sanofi's Ridgefield, New Jersey Site >TMO

2 sept 2025, 12:08 UTC

Adquisiciones, fusiones, absorciones

Solventum Had Seen 2025 Adjusted EPS $5.80-$5.95 >SOLV

2 sept 2025, 12:08 UTC

Adquisiciones, fusiones, absorciones

Solventum Raises 2025 View To Adj EPS $5.88-Adj EPS $6.03 >SOLV

2 sept 2025, 12:04 UTC

Adquisiciones, fusiones, absorciones

Solventum to Use Net Proceeds Primarily to Pay Down Debt >SOLV

2 sept 2025, 12:03 UTC

Adquisiciones, fusiones, absorciones

Solventum Closes Sale of Unit to Thermo Fisher for $4 Billion in Cash >SOLV

2 sept 2025, 12:03 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher Completes Acquisition of Purification & Filtration Business of Solventum for About $4B in Cash >TMO

2 sept 2025, 12:00 UTC

Adquisiciones, fusiones, absorciones

Solventum Completes Sale of Purification & Filtration Business to Thermo Fisher Scientific >SOLV TMO

Comparación entre iguales

Cambio de precio

Thermo Fisher Scientific Inc previsión

Precio Objetivo

By TipRanks

37.33% repunte

Estimación a 12 Meses

Media 671.33 USD  37.33%

Máximo 710 USD

Mínimo 615 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Thermo Fisher Scientific Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

12

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

406.5 / 417.79Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

59 / 349 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar